Mendus
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Mendus is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer treatment. The company focuses on preventing tumor recurrence by stimulating the patient's immune system to build active immunity against residual cancer cells. Specializing in allogeneic dendritic cell biology, Mendus aims to improve long-term survival outcomes and preserve the quality of life for cancer patients. Its lead product candidate, vididencel, is under development for various malignancies, including ovarian cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-28 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Mendus AB (publ)
|
Swedish | 123.8 KB | ||
| 2025-11-28 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Mendus AB (publ)
|
English | 123.1 KB | ||
| 2025-11-18 23:45 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Mendus AB (publ)
|
Swedish | 145.4 KB | ||
| 2025-11-18 23:45 |
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Mendus AB (publ)
|
English | 147.5 KB | ||
| 2025-11-18 23:41 |
Share Issue/Capital Change
Mendus har framgångsrikt genomfört en riktad nyemission om cirka 52,5 miljoner …
|
Swedish | 151.0 KB | ||
| 2025-11-18 23:41 |
Share Issue/Capital Change
Mendus announces successful execution of a directed share issue of approximatel…
|
English | 150.6 KB | ||
| 2025-11-18 17:31 |
Share Issue/Capital Change
Mendus avser att genomföra en riktad nyemission av aktier om cirka 50 miljoner …
|
Swedish | 154.0 KB | ||
| 2025-11-18 17:31 |
Share Issue/Capital Change
Mendus announces its intention to carry out a directed issue of shares of appro…
|
English | 150.5 KB | ||
| 2025-11-13 08:00 |
Quarterly Report
|
Swedish | 1.5 MB | ||
| 2025-11-13 08:00 |
Quarterly Report
|
English | 1.5 MB | ||
| 2025-11-06 08:00 |
Board/Management Information
Mendus Announces Nomination Committee for the 2026 Annual General Meeting
|
English | 118.1 KB | ||
| 2025-11-06 08:00 |
Board/Management Information
Mendus tillkännager valberedning inför årsstämman 2026
|
Swedish | 118.2 KB | ||
| 2025-10-02 08:00 |
Regulatory Filings
Mendus meddelar uppdaterad klinisk strategi och operativt fokus
|
Swedish | 138.6 KB | ||
| 2025-10-02 08:00 |
Regulatory Filings
Mendus announces updated clinical strategy and operational focus
|
English | 137.5 KB | ||
| 2025-08-21 08:00 |
Quarterly Report
|
Swedish | 1.4 MB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-05-19 | Ann-Charlotte Ferm | Other | Buy | 100,000 | 215,900.00 SEK |
| 2022-02-24 | Jeroen Rovers | Other | Buy | 10,000 | 22,100.00 SEK |
| 2022-02-23 | Ann-Charlotte Ferm | Other | Buy | 10,000 | 25,650.00 SEK |
| 2022-02-23 | Erik Manting | Other | Buy | 84,000 | 211,680.00 SEK |
| 2022-02-22 | Ann-Charlotte Ferm | Other | Buy | 10,000 | 23,639.00 SEK |
| 2022-02-22 | Ann-Charlotte Ferm | Other | Buy | 10,000 | 23,394.00 SEK |
| 2022-02-22 | Ann-Charlotte Ferm | Other | Buy | 20,000 | 47,472.00 SEK |
| 2021-12-28 | Johannes Preusting | Other | Buy | 22,500 | 89,100.00 SEK |
| 2021-12-27 | Johannes Preusting | Other | Buy | 27,500 | 97,625.00 SEK |
| 2021-12-23 | Christine Lind | Other | Buy | 30,000 | 104,100.00 SEK |
Peer Companies
